董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lewis H. Bender | 男 | Director,President,Chief Executive Officer and Chairman | 67 | 135.55万美元 | 15.98 | 2026-03-01 |
| Emer Leahy | 女 | Independent Director | 60 | 9.13万美元 | 0.64 | 2026-03-01 |
| Mark A. Goldberg | 男 | Independent Director | 66 | 9.13万美元 | 0.60 | 2026-03-01 |
| Daniel Donovan | 男 | Independent Director | 61 | 8.43万美元 | 0.35 | 2026-03-01 |
| Thomas I.H. Dubin | 男 | Director | 64 | 7.43万美元 | 0.25 | 2026-03-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lewis H. Bender | 男 | Director,President,Chief Executive Officer and Chairman | 67 | 135.55万美元 | 15.98 | 2026-03-01 |
| John Wesolowski | 男 | Principal Accounting Officer and Controller | 66 | 37.85万美元 | 1.02 | 2026-03-01 |
| Joseph Talamo | 男 | Chief Financial Officer | 57 | 72.37万美元 | 1.44 | 2026-03-01 |
董事简历
中英对照 | 中文 | 英文- Lewis H. Bender
-
Lewis H. Bender是Intensity Therapeutics公司创始人，自2012年4月起担任Intensity Therapeutics, Inc.总裁兼首席执行官。在Intensity Therapeutics，Inc.创立之前，Bender先生在2008年至2012年期间担任公开交易（AMEX & OTC）Interleukin Genetics公司的首席执行官。白细胞介素是一家个性化医疗公司。Bender先生通过与机构投资者的直接配售成功地为Intensity Therapeutics公司筹集了资金，并与保险业合作开发了一种IG产品。在加入Interleukin Genetics之前，Bender先生曾在Emisphere Technologies，Inc.担任多个职位，该公司当时是一家公开上市（纳斯达克）的药物递送公司，专门从事口服递送吸收不良分子的开发。从1993年到2007年12月在Emisphere工作期间，本德尔先生担任过临时总裁兼首席执行官、首席技术官、业务发展高级副总裁以及制造和工艺发展副总裁等职务。Bender先生拥有超过26年的生物技术和制药高管管理经验。他领导的开发团队将化合物Intensity Therapeutics，Inc.的新药物递送技术从发现到3期。本德尔拥有麻省理工学院化学工程学士和硕士学位，宾夕法尼亚大学沃顿商学院MBA学位，宾夕法尼亚大学国际研究硕士学位。他能说流利的法语和德语。
Lewis H. Bender is Intensity Therapeutics, Inc. founder and has served as Intensity Therapeutics, Inc. President and Chief Executive Officer since April 2012. Prior to Intensity Therapeutics, Inc. founding, Mr. Bender was the CEO of publicly traded (AMEX & OTC) Interleukin Genetics, Inc. from 2008 until 2012. Interleukin was a personalized medicine company. Mr. Bender was successful in raising capital for via a direct placement with institutional investors and partnered with the insurance industry for development of an IG product. Prior to joining Interleukin Genetics, Mr. Bender held numerous positions at Emisphere Technologies, Inc. at the time a publicly traded (Nasdaq) drug delivery company specializing in the development of oral delivery of poorly absorbed molecules. While at Emisphere from 1993 to December 2007, Mr. Bender held positions including Interim President & CEO, Chief Technology Officer, Senior Vice President of Business Development, and Vice President of Manufacturing and Process Development. Mr. Bender has over 26 years of biotech and pharmaceutical executive management experience. He has led development teams taking products from discovery to Phase 3 for compounds using novel drug delivery techniques. Mr. Bender has a both a BS and MS in Chemical Engineering from The Massachusetts Institute of Technology (MIT), an MBA from the University of Pennsylvania's Wharton School, and an MA in International Studies also from the University of Pennsylvania. He is fluent in French and German. - Lewis H. Bender是Intensity Therapeutics公司创始人，自2012年4月起担任Intensity Therapeutics, Inc.总裁兼首席执行官。在Intensity Therapeutics，Inc.创立之前，Bender先生在2008年至2012年期间担任公开交易（AMEX & OTC）Interleukin Genetics公司的首席执行官。白细胞介素是一家个性化医疗公司。Bender先生通过与机构投资者的直接配售成功地为Intensity Therapeutics公司筹集了资金，并与保险业合作开发了一种IG产品。在加入Interleukin Genetics之前，Bender先生曾在Emisphere Technologies，Inc.担任多个职位，该公司当时是一家公开上市（纳斯达克）的药物递送公司，专门从事口服递送吸收不良分子的开发。从1993年到2007年12月在Emisphere工作期间，本德尔先生担任过临时总裁兼首席执行官、首席技术官、业务发展高级副总裁以及制造和工艺发展副总裁等职务。Bender先生拥有超过26年的生物技术和制药高管管理经验。他领导的开发团队将化合物Intensity Therapeutics，Inc.的新药物递送技术从发现到3期。本德尔拥有麻省理工学院化学工程学士和硕士学位，宾夕法尼亚大学沃顿商学院MBA学位，宾夕法尼亚大学国际研究硕士学位。他能说流利的法语和德语。
- Lewis H. Bender is Intensity Therapeutics, Inc. founder and has served as Intensity Therapeutics, Inc. President and Chief Executive Officer since April 2012. Prior to Intensity Therapeutics, Inc. founding, Mr. Bender was the CEO of publicly traded (AMEX & OTC) Interleukin Genetics, Inc. from 2008 until 2012. Interleukin was a personalized medicine company. Mr. Bender was successful in raising capital for via a direct placement with institutional investors and partnered with the insurance industry for development of an IG product. Prior to joining Interleukin Genetics, Mr. Bender held numerous positions at Emisphere Technologies, Inc. at the time a publicly traded (Nasdaq) drug delivery company specializing in the development of oral delivery of poorly absorbed molecules. While at Emisphere from 1993 to December 2007, Mr. Bender held positions including Interim President & CEO, Chief Technology Officer, Senior Vice President of Business Development, and Vice President of Manufacturing and Process Development. Mr. Bender has over 26 years of biotech and pharmaceutical executive management experience. He has led development teams taking products from discovery to Phase 3 for compounds using novel drug delivery techniques. Mr. Bender has a both a BS and MS in Chemical Engineering from The Massachusetts Institute of Technology (MIT), an MBA from the University of Pennsylvania's Wharton School, and an MA in International Studies also from the University of Pennsylvania. He is fluent in French and German.
- Emer Leahy
-
Emer Leahy，自2016年6月起担任Intensity Therapeutics，Inc.董事会董事。Leahy博士在爱尔兰都柏林大学学院获得神经药理学博士学位，在哥伦比亚大学获得MBA学位。自2000年以来，她一直担任PsychoGenics Inc.的首席执行官，这是一家盈利的临床前CNS服务公司。她还是PGI Drug Discovery LLC的首席执行官，该公司从事精神药物发现，有五个合作临床项目，其中一个处于第三阶段。此外，她还在西奈山医学院担任神经科学兼职副教授。Leahy博士在制药和生物技术公司的药物发现、临床开发和业务发展方面拥有30多年的经验，包括广泛的技术评估、许可、并购和战略规划方面的知识。Leahy博士曾在生物技术产业组织（BIO）董事会的新兴公司科理事会、阿尔茨海默氏症药物发现基金会的商业审查委员会和国际雷特综合症基金会的科学咨询委员会任职。她目前还担任PsychoGenics公司、Bright Minds生物科学公司、Pasithea治疗公司和BIONJ公司董事会的董事。
Emer Leahy has served on Board since June 2021. Dr. Leahy received her Ph.D. in neuropharmacology from University College Dublin, Ireland in 1990, and her MBA from Columbia University in 2000. She has been with PsychoGenics Inc., a preclinical CNS service company, since 1999 and is currently serving as its chief executive officer, where she is responsible for compensation recommendations companywide. Prior to her appointment as chief executive officer, she was the vice president of business development. Dr. Leahy is also the chief executive officer of PGI Drug Discovery LLC, a company engaged in psychiatric drug discovery with five partnered clinical programs including one in Phase III. Additionally, Dr. Leahy served as a member of both the compensation committee and the audit committee of Bright Minds Biosciences Inc. (NASDAQ: DRUG), a biotech company, until April 2022. Since 2016, Dr. Leahy has served as a member of the board of directors of Intensity Therapeutics, Inc. With more than 30 years of experience in drug discovery, clinical development and business development for pharmaceutical and biotechnology companies, Dr. Leahy possesses extensive knowledge of technology assessment, licensing, mergers and acquisitions, and strategic planning. She is also an Adjunct Associate Professor of Neuroscience at Mount Sinai School of Medicine. Dr. Leahy has also served on the Emerging Companies Section Governing Board for the Board of the Biotechnology Industry Organization, the Business Review Board for the Alzheimer's Drug Discovery Foundation, and the Scientific Advisory Board of the International Rett Syndrome Foundation. She also currently serves on the Board of PsychoGenics Inc, the Board of Intensity Therapeutics, and is the Chair of the Board of Trustees of BioNJ. - Emer Leahy，自2016年6月起担任Intensity Therapeutics，Inc.董事会董事。Leahy博士在爱尔兰都柏林大学学院获得神经药理学博士学位，在哥伦比亚大学获得MBA学位。自2000年以来，她一直担任PsychoGenics Inc.的首席执行官，这是一家盈利的临床前CNS服务公司。她还是PGI Drug Discovery LLC的首席执行官，该公司从事精神药物发现，有五个合作临床项目，其中一个处于第三阶段。此外，她还在西奈山医学院担任神经科学兼职副教授。Leahy博士在制药和生物技术公司的药物发现、临床开发和业务发展方面拥有30多年的经验，包括广泛的技术评估、许可、并购和战略规划方面的知识。Leahy博士曾在生物技术产业组织（BIO）董事会的新兴公司科理事会、阿尔茨海默氏症药物发现基金会的商业审查委员会和国际雷特综合症基金会的科学咨询委员会任职。她目前还担任PsychoGenics公司、Bright Minds生物科学公司、Pasithea治疗公司和BIONJ公司董事会的董事。
- Emer Leahy has served on Board since June 2021. Dr. Leahy received her Ph.D. in neuropharmacology from University College Dublin, Ireland in 1990, and her MBA from Columbia University in 2000. She has been with PsychoGenics Inc., a preclinical CNS service company, since 1999 and is currently serving as its chief executive officer, where she is responsible for compensation recommendations companywide. Prior to her appointment as chief executive officer, she was the vice president of business development. Dr. Leahy is also the chief executive officer of PGI Drug Discovery LLC, a company engaged in psychiatric drug discovery with five partnered clinical programs including one in Phase III. Additionally, Dr. Leahy served as a member of both the compensation committee and the audit committee of Bright Minds Biosciences Inc. (NASDAQ: DRUG), a biotech company, until April 2022. Since 2016, Dr. Leahy has served as a member of the board of directors of Intensity Therapeutics, Inc. With more than 30 years of experience in drug discovery, clinical development and business development for pharmaceutical and biotechnology companies, Dr. Leahy possesses extensive knowledge of technology assessment, licensing, mergers and acquisitions, and strategic planning. She is also an Adjunct Associate Professor of Neuroscience at Mount Sinai School of Medicine. Dr. Leahy has also served on the Emerging Companies Section Governing Board for the Board of the Biotechnology Industry Organization, the Business Review Board for the Alzheimer's Drug Discovery Foundation, and the Scientific Advisory Board of the International Rett Syndrome Foundation. She also currently serves on the Board of PsychoGenics Inc, the Board of Intensity Therapeutics, and is the Chair of the Board of Trustees of BioNJ.
- Mark A. Goldberg
-
Mark A. Goldberg，自2018年5月起担任Intensity Therapeutics，Inc.董事会成员。Mark A. Goldberg博士最近担任PAREXEL国际公司的总裁兼首席运营官。PAREXEL国际公司是全球最大的生物制药服务提供商之一，其综合服务收入约为21亿美元，拥有超过18000名员工，在51个国家和地区设有86个办事处。他负责监督所有创收业务部门，包括临床研究服务、PAREXEL Informatics和PAREXEL Consulting，以及销售、营销、企业质量和信息技术。戈德伯格博士帮助开创了PAREXEL与一些世界领先制药公司的战略合作方式，并通过有机增长和收购，建立了该公司的全球基础设施，特别是在亚太地区。在PAREXEL职业生涯的早期，他创立了公司的医学影像业务，并帮助成立了技术子公司Perceptive Informatics（现为PAREXEL Informatics）。戈德伯格博士拥有麻省理工学院的计算机科学学士学位和马萨诸塞大学医学院的医学博士学位。他在麻省总医院完成了放射学住院医师培训，并在哈佛医学院担任首席住院医师和学术任命的医师。
Mark A. Goldberg has served as a member of Intensity Therapeutics, Inc. board of directors since May 2018. Since January 2026, Dr. Goldberg has served as Operating Partner of Arsenal Capital Management, a specialized private equity firm in the industrials and healthcare sectors. Since 2019, Dr. Goldberg has served as Chairman of Allucent, a global mid sized clinical research organization, and has also served as Chief Executive Officer between 2019 and 2024. Dr. Goldberg has also served as the Executive Chairman of Thread, a decentralized research and electronic clinical outcome assessment provider, between 2019 and 2024. Previously, Dr. Goldberg has served as President and COO of PAREXEL International, one of the world's largest global biopharmaceutical service providers, with consolidated revenue of approximately $2.4 billion in 2017, over 18,000 employees, and 86 locations in 51 countries. He was responsible for overseeing all revenue generating business segments including Clinical Research Services, PAREXEL Informatics, and PAREXEL Consulting as well as sales, marketing, corporate quality, and information technology. Dr. Goldberg helped to pioneer PAREXEL's strategic partnering approach with some of the world's leading pharmaceutical companies and to build out the company's global infrastructure, particularly in the Asia Pacific region, through both organic growth and acquisitions. Earlier in his PAREXEL career, he founded the company's Medical Imaging business and helped establish its technology subsidiary, PAREXEL Informatics. Dr. Goldberg holds a BS degree in computer science from MIT and an MD from the University of Massachusetts Medical School. He completed residency training in Radiology at Massachusetts General Hospital, where he also served as Chief Resident and a staff physician with academic appointments at Harvard Medical School. - Mark A. Goldberg，自2018年5月起担任Intensity Therapeutics，Inc.董事会成员。Mark A. Goldberg博士最近担任PAREXEL国际公司的总裁兼首席运营官。PAREXEL国际公司是全球最大的生物制药服务提供商之一，其综合服务收入约为21亿美元，拥有超过18000名员工，在51个国家和地区设有86个办事处。他负责监督所有创收业务部门，包括临床研究服务、PAREXEL Informatics和PAREXEL Consulting，以及销售、营销、企业质量和信息技术。戈德伯格博士帮助开创了PAREXEL与一些世界领先制药公司的战略合作方式，并通过有机增长和收购，建立了该公司的全球基础设施，特别是在亚太地区。在PAREXEL职业生涯的早期，他创立了公司的医学影像业务，并帮助成立了技术子公司Perceptive Informatics（现为PAREXEL Informatics）。戈德伯格博士拥有麻省理工学院的计算机科学学士学位和马萨诸塞大学医学院的医学博士学位。他在麻省总医院完成了放射学住院医师培训，并在哈佛医学院担任首席住院医师和学术任命的医师。
- Mark A. Goldberg has served as a member of Intensity Therapeutics, Inc. board of directors since May 2018. Since January 2026, Dr. Goldberg has served as Operating Partner of Arsenal Capital Management, a specialized private equity firm in the industrials and healthcare sectors. Since 2019, Dr. Goldberg has served as Chairman of Allucent, a global mid sized clinical research organization, and has also served as Chief Executive Officer between 2019 and 2024. Dr. Goldberg has also served as the Executive Chairman of Thread, a decentralized research and electronic clinical outcome assessment provider, between 2019 and 2024. Previously, Dr. Goldberg has served as President and COO of PAREXEL International, one of the world's largest global biopharmaceutical service providers, with consolidated revenue of approximately $2.4 billion in 2017, over 18,000 employees, and 86 locations in 51 countries. He was responsible for overseeing all revenue generating business segments including Clinical Research Services, PAREXEL Informatics, and PAREXEL Consulting as well as sales, marketing, corporate quality, and information technology. Dr. Goldberg helped to pioneer PAREXEL's strategic partnering approach with some of the world's leading pharmaceutical companies and to build out the company's global infrastructure, particularly in the Asia Pacific region, through both organic growth and acquisitions. Earlier in his PAREXEL career, he founded the company's Medical Imaging business and helped establish its technology subsidiary, PAREXEL Informatics. Dr. Goldberg holds a BS degree in computer science from MIT and an MD from the University of Massachusetts Medical School. He completed residency training in Radiology at Massachusetts General Hospital, where he also served as Chief Resident and a staff physician with academic appointments at Harvard Medical School.
- Daniel Donovan
-
Daniel Donovan于2023年1月加入董事会。自2014年至今，他一直担任rareLife Solutions，Inc.的首席执行官，该公司创建连接，以吸引、统一和扩大患者、倡导者和护理人员的声音，为新兴疗法的开发和商业化提供信息和加速，特别是在罕见病方面。丹是癌症预防制药（CPP）的董事会成员和首席商务官，这是一家药物开发公司的后期阶段，针对几种罕见疾病的化合物。在加入rereLife和CPP之前，Dan在2001年成立了远景制药，担任总裁至2011年6月。他是创建和发展Datavision的远见卓识者，Datavision是医学出版物技术的市场领导者。Envision Pharma于2008年4月被United BioSource Corporation（UBC）收购。在UBC，Daniel Donovan先生是战略和市场开发高级副总裁。丹的职业生涯始于辉瑞，担任过各种职务，责任越来越大，从销售到市场研究，以及在美国国内和国际市场的市场营销，并最终担任董事和欧洲团队负责人。在辉瑞工作期间，他在制药行业一些最成功的产品的商业化过程中发挥了关键作用。Dan在利哈伊大学获得金融学理学学士学位。
Daniel Donovan has served as a member of Intensity Therapeutics, Inc. board of directors since January 2023. Mr. Daniel Donovan is an entrepreneur with extensive experience within the biotech industry. Since 2014 to present he has been the Chief Executive Officer of rareLife Solutions, Inc., a company creating the connections to engage, unify, and amplify the voices of patients, advocates, and caregivers to inform and accelerate the development and commercialization of emerging treatments especially in rare diseases. Dan was a member of the Board of Directors and Chief Business Officer at Cancer Prevention Pharmaceuticals (CPP), a late stage pharmaceutical development company with compounds targeted at several rare diseases. Prior to rareLife and CPP, Dan established Envision Pharma in 2001, serving as President through June 2011. He was the visionary behind the creation and development of Datavision, the market leader in medical publications technology. Envision Pharma was acquired by the United BioSource Corporation (UBC) in April 2008. At UBC Mr. Daniel Donovan was Senior Vice President Strategy and Market Development. Dan began his career at Pfizer serving in a variety of positions of increasing responsibility, ranging from sales to market research and marketing in the US domestic and international market place, culminating in his position as Director and European Team Leader. During his time at Pfizer, he played a pivotal role in the commercialization of some of the pharmaceutical industry's most successful product launches. Dan earned a Bachelor of Science degree in Finance at Lehigh University. - Daniel Donovan于2023年1月加入董事会。自2014年至今，他一直担任rareLife Solutions，Inc.的首席执行官，该公司创建连接，以吸引、统一和扩大患者、倡导者和护理人员的声音，为新兴疗法的开发和商业化提供信息和加速，特别是在罕见病方面。丹是癌症预防制药（CPP）的董事会成员和首席商务官，这是一家药物开发公司的后期阶段，针对几种罕见疾病的化合物。在加入rereLife和CPP之前，Dan在2001年成立了远景制药，担任总裁至2011年6月。他是创建和发展Datavision的远见卓识者，Datavision是医学出版物技术的市场领导者。Envision Pharma于2008年4月被United BioSource Corporation（UBC）收购。在UBC，Daniel Donovan先生是战略和市场开发高级副总裁。丹的职业生涯始于辉瑞，担任过各种职务，责任越来越大，从销售到市场研究，以及在美国国内和国际市场的市场营销，并最终担任董事和欧洲团队负责人。在辉瑞工作期间，他在制药行业一些最成功的产品的商业化过程中发挥了关键作用。Dan在利哈伊大学获得金融学理学学士学位。
- Daniel Donovan has served as a member of Intensity Therapeutics, Inc. board of directors since January 2023. Mr. Daniel Donovan is an entrepreneur with extensive experience within the biotech industry. Since 2014 to present he has been the Chief Executive Officer of rareLife Solutions, Inc., a company creating the connections to engage, unify, and amplify the voices of patients, advocates, and caregivers to inform and accelerate the development and commercialization of emerging treatments especially in rare diseases. Dan was a member of the Board of Directors and Chief Business Officer at Cancer Prevention Pharmaceuticals (CPP), a late stage pharmaceutical development company with compounds targeted at several rare diseases. Prior to rareLife and CPP, Dan established Envision Pharma in 2001, serving as President through June 2011. He was the visionary behind the creation and development of Datavision, the market leader in medical publications technology. Envision Pharma was acquired by the United BioSource Corporation (UBC) in April 2008. At UBC Mr. Daniel Donovan was Senior Vice President Strategy and Market Development. Dan began his career at Pfizer serving in a variety of positions of increasing responsibility, ranging from sales to market research and marketing in the US domestic and international market place, culminating in his position as Director and European Team Leader. During his time at Pfizer, he played a pivotal role in the commercialization of some of the pharmaceutical industry's most successful product launches. Dan earned a Bachelor of Science degree in Finance at Lehigh University.
- Thomas I.H. Dubin
-
Thomas I.H. Dubin博士，自2010年1月起担任高级副总裁和首席法务官。2005年8月到2009年12月担任高级副总裁和总法律顾问；2001年1月到2005年7月担任副总裁和总法律顾问。1999年2月到2000年9月他担任ChiRex Inc.（一家上市的国际公司，为制药行业提供高级进程开发服务和特殊制造）副总裁、总法律顾问和秘书。该公司于2000年9月被Rhodia收购并与之合并。1992年到1999年Dubin在Warner-Lambert Company担任多个职位，包括担任Pharmaceuticals助理总法律顾问。在Warner-Lambert任职期间， Dubin在 Cravath Swaine & Moore纽约办事处担任5年的企业律师。Dubin持有New York University法律博士学位并以优异成绩获得Amherst College文学学士学位。
Thomas I.H. Dubin has been a director since September 2015. Mr. Dubin is an attorney and has over twenty years of senior leadership experience in the pharmaceutical and biotechnology industries. From January 2014 through November 2014 Mr. Dubin served as an advisor to the Chief Executive Officer of Infinity Pharmaceuticals Inc. NASDAQ: INFI. From 2008 through 2013 he was Senior Vice President and Chief Legal Officer, and from 2001 through 2008 he was Vice President and General Counsel, of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Prior to Alexion, from 1992 to 2000 Mr. Dubin served in senior positions at ChiRex, Inc. (NASDAQ:CHRX) and at Warner-Lambert Company (NYSE:WLA) prior to its sale to Pfizer, Inc. Mr. Dubin began his career as an attorney with Cravath, Swaine & Moore LLP in New York City. He is a Trustee of the American Jewish World Service, and a Member of Launchpad Venture Group. Mr. Dubin received his J.D. from New York University School of Law, and his B.A. from Amherst College, cum laude. - Thomas I.H. Dubin博士，自2010年1月起担任高级副总裁和首席法务官。2005年8月到2009年12月担任高级副总裁和总法律顾问；2001年1月到2005年7月担任副总裁和总法律顾问。1999年2月到2000年9月他担任ChiRex Inc.（一家上市的国际公司，为制药行业提供高级进程开发服务和特殊制造）副总裁、总法律顾问和秘书。该公司于2000年9月被Rhodia收购并与之合并。1992年到1999年Dubin在Warner-Lambert Company担任多个职位，包括担任Pharmaceuticals助理总法律顾问。在Warner-Lambert任职期间， Dubin在 Cravath Swaine & Moore纽约办事处担任5年的企业律师。Dubin持有New York University法律博士学位并以优异成绩获得Amherst College文学学士学位。
- Thomas I.H. Dubin has been a director since September 2015. Mr. Dubin is an attorney and has over twenty years of senior leadership experience in the pharmaceutical and biotechnology industries. From January 2014 through November 2014 Mr. Dubin served as an advisor to the Chief Executive Officer of Infinity Pharmaceuticals Inc. NASDAQ: INFI. From 2008 through 2013 he was Senior Vice President and Chief Legal Officer, and from 2001 through 2008 he was Vice President and General Counsel, of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Prior to Alexion, from 1992 to 2000 Mr. Dubin served in senior positions at ChiRex, Inc. (NASDAQ:CHRX) and at Warner-Lambert Company (NYSE:WLA) prior to its sale to Pfizer, Inc. Mr. Dubin began his career as an attorney with Cravath, Swaine & Moore LLP in New York City. He is a Trustee of the American Jewish World Service, and a Member of Launchpad Venture Group. Mr. Dubin received his J.D. from New York University School of Law, and his B.A. from Amherst College, cum laude.
高管简历
中英对照 | 中文 | 英文- Lewis H. Bender
Lewis H. Bender是Intensity Therapeutics公司创始人，自2012年4月起担任Intensity Therapeutics, Inc.总裁兼首席执行官。在Intensity Therapeutics，Inc.创立之前，Bender先生在2008年至2012年期间担任公开交易（AMEX & OTC）Interleukin Genetics公司的首席执行官。白细胞介素是一家个性化医疗公司。Bender先生通过与机构投资者的直接配售成功地为Intensity Therapeutics公司筹集了资金，并与保险业合作开发了一种IG产品。在加入Interleukin Genetics之前，Bender先生曾在Emisphere Technologies，Inc.担任多个职位，该公司当时是一家公开上市（纳斯达克）的药物递送公司，专门从事口服递送吸收不良分子的开发。从1993年到2007年12月在Emisphere工作期间，本德尔先生担任过临时总裁兼首席执行官、首席技术官、业务发展高级副总裁以及制造和工艺发展副总裁等职务。Bender先生拥有超过26年的生物技术和制药高管管理经验。他领导的开发团队将化合物Intensity Therapeutics，Inc.的新药物递送技术从发现到3期。本德尔拥有麻省理工学院化学工程学士和硕士学位，宾夕法尼亚大学沃顿商学院MBA学位，宾夕法尼亚大学国际研究硕士学位。他能说流利的法语和德语。
Lewis H. Bender is Intensity Therapeutics, Inc. founder and has served as Intensity Therapeutics, Inc. President and Chief Executive Officer since April 2012. Prior to Intensity Therapeutics, Inc. founding, Mr. Bender was the CEO of publicly traded (AMEX & OTC) Interleukin Genetics, Inc. from 2008 until 2012. Interleukin was a personalized medicine company. Mr. Bender was successful in raising capital for via a direct placement with institutional investors and partnered with the insurance industry for development of an IG product. Prior to joining Interleukin Genetics, Mr. Bender held numerous positions at Emisphere Technologies, Inc. at the time a publicly traded (Nasdaq) drug delivery company specializing in the development of oral delivery of poorly absorbed molecules. While at Emisphere from 1993 to December 2007, Mr. Bender held positions including Interim President & CEO, Chief Technology Officer, Senior Vice President of Business Development, and Vice President of Manufacturing and Process Development. Mr. Bender has over 26 years of biotech and pharmaceutical executive management experience. He has led development teams taking products from discovery to Phase 3 for compounds using novel drug delivery techniques. Mr. Bender has a both a BS and MS in Chemical Engineering from The Massachusetts Institute of Technology (MIT), an MBA from the University of Pennsylvania's Wharton School, and an MA in International Studies also from the University of Pennsylvania. He is fluent in French and German.- Lewis H. Bender是Intensity Therapeutics公司创始人，自2012年4月起担任Intensity Therapeutics, Inc.总裁兼首席执行官。在Intensity Therapeutics，Inc.创立之前，Bender先生在2008年至2012年期间担任公开交易（AMEX & OTC）Interleukin Genetics公司的首席执行官。白细胞介素是一家个性化医疗公司。Bender先生通过与机构投资者的直接配售成功地为Intensity Therapeutics公司筹集了资金，并与保险业合作开发了一种IG产品。在加入Interleukin Genetics之前，Bender先生曾在Emisphere Technologies，Inc.担任多个职位，该公司当时是一家公开上市（纳斯达克）的药物递送公司，专门从事口服递送吸收不良分子的开发。从1993年到2007年12月在Emisphere工作期间，本德尔先生担任过临时总裁兼首席执行官、首席技术官、业务发展高级副总裁以及制造和工艺发展副总裁等职务。Bender先生拥有超过26年的生物技术和制药高管管理经验。他领导的开发团队将化合物Intensity Therapeutics，Inc.的新药物递送技术从发现到3期。本德尔拥有麻省理工学院化学工程学士和硕士学位，宾夕法尼亚大学沃顿商学院MBA学位，宾夕法尼亚大学国际研究硕士学位。他能说流利的法语和德语。
- Lewis H. Bender is Intensity Therapeutics, Inc. founder and has served as Intensity Therapeutics, Inc. President and Chief Executive Officer since April 2012. Prior to Intensity Therapeutics, Inc. founding, Mr. Bender was the CEO of publicly traded (AMEX & OTC) Interleukin Genetics, Inc. from 2008 until 2012. Interleukin was a personalized medicine company. Mr. Bender was successful in raising capital for via a direct placement with institutional investors and partnered with the insurance industry for development of an IG product. Prior to joining Interleukin Genetics, Mr. Bender held numerous positions at Emisphere Technologies, Inc. at the time a publicly traded (Nasdaq) drug delivery company specializing in the development of oral delivery of poorly absorbed molecules. While at Emisphere from 1993 to December 2007, Mr. Bender held positions including Interim President & CEO, Chief Technology Officer, Senior Vice President of Business Development, and Vice President of Manufacturing and Process Development. Mr. Bender has over 26 years of biotech and pharmaceutical executive management experience. He has led development teams taking products from discovery to Phase 3 for compounds using novel drug delivery techniques. Mr. Bender has a both a BS and MS in Chemical Engineering from The Massachusetts Institute of Technology (MIT), an MBA from the University of Pennsylvania's Wharton School, and an MA in International Studies also from the University of Pennsylvania. He is fluent in French and German.
- John Wesolowski
John Wesolowski，自2023年6月起担任Intensity Therapeutics, Inc.临时首席财务官，自2017年3月起担任Intensity Therapeutics, Inc.首席会计官和财务总监。在加入Intensity Therapeutics之前，从1998年到2016年，Wesolowski先生是耶鲁大学财务总监办公室的成本主管。Wesolowski先生担任这一职务，负责财务报告、财产税管理，负责计算间接费用和福利率，并参与了许多与会计程序和控制有关的特别项目。此外，在耶鲁大学，他参与了财务报告以及与临床试验和其他有组织的研究有关的会计事务。在加入耶鲁大学之前，Wesolowski先生于1988年至1998年担任康涅狄格州布兰福德自动紧固件公司的副总裁兼财务总监。Wesolowski先生担任这一职务，负责所有会计、采购和人力资源职能。约翰还在KMG Main Hurdman（现为毕马威）拥有5年的公共会计和审计经验。Wesolowski先生在宾夕法尼亚州立大学（University Park的宾夕法尼亚州立大学）获得金融学学士学位，在康涅狄格大学获得管理学MBA学位。他自1983年以来一直是注册公众帐号。
John Wesolowski has served as Intensity Therapeutics, Inc. Principal Accounting Officer and Controller since March 2017. In addition, Mr. Wesolowski served as Intensity Therapeutics, Inc. Interim Chief Financial Officer from June 2023 until December 2023. Prior to joining Intensity Therapeutics, from 1998 to 2016 Mr. Wesolowski was Director of Costing in the Yale University Controller's office. In that role Mr. Wesolowski conducted financial reporting, property tax management, was responsible for calculations of overhead and benefit rates, and was involved in numerous special projects related to accounting process and controls. Also, at Yale, he was involved in financial reporting and the accounting matters related to clinical trials and other organized research. Prior to joining Yale Mr. Wesolowski was the Vice President and Controller for Automatic Fastener Corporation in Branford, CT from 1988 to 1998. In this role, Mr. Wesolowski oversaw all accounting, purchasing and human resource functions. John also has 5 years of experience in public accounting and auditing from working at KMG Main Hurdman, now KPMG. Mr. Wesolowski received a Bachelor of Science in Finance from The Pennsylvania State University (Penn State at University Park) and an MBA from the University of Connecticut in Management Science. He is a Certified Public Accountant since 1983.- John Wesolowski，自2023年6月起担任Intensity Therapeutics, Inc.临时首席财务官，自2017年3月起担任Intensity Therapeutics, Inc.首席会计官和财务总监。在加入Intensity Therapeutics之前，从1998年到2016年，Wesolowski先生是耶鲁大学财务总监办公室的成本主管。Wesolowski先生担任这一职务，负责财务报告、财产税管理，负责计算间接费用和福利率，并参与了许多与会计程序和控制有关的特别项目。此外，在耶鲁大学，他参与了财务报告以及与临床试验和其他有组织的研究有关的会计事务。在加入耶鲁大学之前，Wesolowski先生于1988年至1998年担任康涅狄格州布兰福德自动紧固件公司的副总裁兼财务总监。Wesolowski先生担任这一职务，负责所有会计、采购和人力资源职能。约翰还在KMG Main Hurdman（现为毕马威）拥有5年的公共会计和审计经验。Wesolowski先生在宾夕法尼亚州立大学（University Park的宾夕法尼亚州立大学）获得金融学学士学位，在康涅狄格大学获得管理学MBA学位。他自1983年以来一直是注册公众帐号。
- John Wesolowski has served as Intensity Therapeutics, Inc. Principal Accounting Officer and Controller since March 2017. In addition, Mr. Wesolowski served as Intensity Therapeutics, Inc. Interim Chief Financial Officer from June 2023 until December 2023. Prior to joining Intensity Therapeutics, from 1998 to 2016 Mr. Wesolowski was Director of Costing in the Yale University Controller's office. In that role Mr. Wesolowski conducted financial reporting, property tax management, was responsible for calculations of overhead and benefit rates, and was involved in numerous special projects related to accounting process and controls. Also, at Yale, he was involved in financial reporting and the accounting matters related to clinical trials and other organized research. Prior to joining Yale Mr. Wesolowski was the Vice President and Controller for Automatic Fastener Corporation in Branford, CT from 1988 to 1998. In this role, Mr. Wesolowski oversaw all accounting, purchasing and human resource functions. John also has 5 years of experience in public accounting and auditing from working at KMG Main Hurdman, now KPMG. Mr. Wesolowski received a Bachelor of Science in Finance from The Pennsylvania State University (Penn State at University Park) and an MBA from the University of Connecticut in Management Science. He is a Certified Public Accountant since 1983.
- Joseph Talamo
Joseph Talamo，从2011年6月起，他担任NeoStem的副总裁、公司主管和首席会计官。从1996至2010年，他在OSI Pharmaceuticals, Inc. "OSI"担任过多个高级职位，该公司是上市制药公司，业务为发现、开发并销售治疗癌症、糖尿病和肥胖的产品，从2006至2010年担任副总裁和公司主管，从2002至2006年担任公司主管。在OSI期间，他帮助建立了会计和财政基础来支持特罗凯（Tarceva）临床开发和商业化运作，该药物是OSI的靶向治疗病人的非小细胞肺癌和胰腺癌抗癌药物。加入OSI之前从1995至1996年，他在Bristol-Myers Squibb的财政报告与总合报告部门工作，从1993至1995年在KPMG卫生保健和生命科学审计部门工作。从2012年起，他还是Stem For Life Foundation的审计官，从2008至2010年，担任OSI Pharmaceuticals Foundation的审计官。1991年，他在Hofstra University获得工商管理会计学学士学位，1999年，在Hofstra University获得工商管理学金融硕士学位。
Joseph Talamo was promoted to Senior Vice President and Chief Financial Officer in October 2015 from his previous role when he joined Caladrius in 2011 as the Corporate Controller and Chief Accounting Officer. From 1996 to 2010 Mr. Talamo held various senior positions at OSI Pharmaceuticals, Inc. "OSI", a publicly-traded biopharmaceutical company focused on discovering, developing and commercializing products for the treatment of cancer, diabetes and obesity, and most recently served as its Vice President and Corporate Controller from 2006 to 2010 and its Corporate Controller from 2002 to 2006. While at OSI, Mr. Talamo helped build the accounting and finance infrastructure to support the clinical development and commercial launch of Tarceva, OSI's targeted therapy approved for the treatment of patients with non-small cell lung cancer and pancreatic cancer. Prior to OSI, Mr. Talamo worked at Bristol-Myers Squibb from 1995 to 1996 in the Financial Reporting and Consolidations Group, and at KPMG from 1993 to 1995 in the Health Care and Life Sciences Audit Group. Mr. Talamo has served as Treasurer of the Stem For Life Foundation, a public charity dedicated to raising awareness about adult stem cells and their therapeutic promise, since 2012. Mr. Talamo also served as Treasurer of the OSI Pharmaceuticals Foundation from 2008 to 2010. Mr. Talamo received a B.B.A. in Accounting from Hofstra University in 1991 and an M.B.A. in Finance from Hofstra University in 1999. Mr. Talamo is a certified public accountant in the State of New York.- Joseph Talamo，从2011年6月起，他担任NeoStem的副总裁、公司主管和首席会计官。从1996至2010年，他在OSI Pharmaceuticals, Inc. "OSI"担任过多个高级职位，该公司是上市制药公司，业务为发现、开发并销售治疗癌症、糖尿病和肥胖的产品，从2006至2010年担任副总裁和公司主管，从2002至2006年担任公司主管。在OSI期间，他帮助建立了会计和财政基础来支持特罗凯（Tarceva）临床开发和商业化运作，该药物是OSI的靶向治疗病人的非小细胞肺癌和胰腺癌抗癌药物。加入OSI之前从1995至1996年，他在Bristol-Myers Squibb的财政报告与总合报告部门工作，从1993至1995年在KPMG卫生保健和生命科学审计部门工作。从2012年起，他还是Stem For Life Foundation的审计官，从2008至2010年，担任OSI Pharmaceuticals Foundation的审计官。1991年，他在Hofstra University获得工商管理会计学学士学位，1999年，在Hofstra University获得工商管理学金融硕士学位。
- Joseph Talamo was promoted to Senior Vice President and Chief Financial Officer in October 2015 from his previous role when he joined Caladrius in 2011 as the Corporate Controller and Chief Accounting Officer. From 1996 to 2010 Mr. Talamo held various senior positions at OSI Pharmaceuticals, Inc. "OSI", a publicly-traded biopharmaceutical company focused on discovering, developing and commercializing products for the treatment of cancer, diabetes and obesity, and most recently served as its Vice President and Corporate Controller from 2006 to 2010 and its Corporate Controller from 2002 to 2006. While at OSI, Mr. Talamo helped build the accounting and finance infrastructure to support the clinical development and commercial launch of Tarceva, OSI's targeted therapy approved for the treatment of patients with non-small cell lung cancer and pancreatic cancer. Prior to OSI, Mr. Talamo worked at Bristol-Myers Squibb from 1995 to 1996 in the Financial Reporting and Consolidations Group, and at KPMG from 1993 to 1995 in the Health Care and Life Sciences Audit Group. Mr. Talamo has served as Treasurer of the Stem For Life Foundation, a public charity dedicated to raising awareness about adult stem cells and their therapeutic promise, since 2012. Mr. Talamo also served as Treasurer of the OSI Pharmaceuticals Foundation from 2008 to 2010. Mr. Talamo received a B.B.A. in Accounting from Hofstra University in 1991 and an M.B.A. in Finance from Hofstra University in 1999. Mr. Talamo is a certified public accountant in the State of New York.